Navigation Links
Alexza Pharmaceuticals Reacquires U.S. and Canadian Rights for AZ-004 (Staccato® Loxapine)
Date:10/19/2010

MOUNTAIN VIEW, Calif., Oct. 19 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has reacquired the U.S. and Canadian rights for AZ-004 (Staccato® loxapine) from Biovail Laboratories International SRL ("BLS"), a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE and TSX: VRX) ("Valeant").  AZ-004 is being developed for the rapid treatment of agitation in schizophrenia or bipolar disorder patients.  Alexza previously established a collaboration arrangement with BLS, to develop and commercialize AZ-004 in the U.S. and Canada, for which Alexza received a $40 million upfront payment.  On September 28, 2010, Biovail Corporation and Valeant Pharmaceuticals International completed their merger.  As part of the review of the merged company's commercial and development pipelines, BLS has decided not to continue the AZ-004 project pursuant to the terms of the agreements between BLS and Alexza.  Based on the comprehensive clinical development program conducted for AZ-004 and the significant unmet medical need for patients, physicians and caregivers, Alexza intends to seek one or more pharmaceutical partners for the worldwide development and commercialization of AZ-004.

"The transaction with BLS has been of great value in allowing us to advance the development of AZ-004 and to expand our understanding of the market opportunity for this novel therapeutic," said Thomas B. King, Alexza President and CEO.  "While we would have been pleased to continue what has been a great working relationship with BLS, we understand BLS' strategic interest in focusing on its core therapeutic areas.  We look forward to advancing the development of AZ-004 and will provide further details regarding this program after we have our follow-on meeting with the FDA."

Under the terms of the agreements, with this
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014 /CNW/ - Bedrocan Cannabis Corp., previously ... members to its Board of Directors, enhancing executive ... the company, a leading licensed producer of medicinal ... Bedrocan has 13 years, experience in producing and ... countries, including Canada. As previously ...
(Date:8/21/2014)... -- Cyberonics, Inc. (NASDAQ: CYBX ) today announced results ... Quarterly highlights 1   Operating results for the ... of fiscal 2014, and other achievements, include: , Worldwide ... , Strong international net sales of $13.2 million, an ... U.S. net product sales reached a new high of $58.8 ...
(Date:8/21/2014)... , Aug. 21, 2014 Asterias Biotherapeutics, Inc. ... field of regenerative medicine, announced today the appointments of ... Company,s newly expanded Board of Directors. With these additions, ... three of whom are independent. Andy ... with emerging growth companies. He is currently Managing Director ...
Breaking Medicine Technology:Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4
... Inc. (Nasdaq: NLTX ), a company focused on ... announced its second quarter financial results for 2010. ... Nile reported a net loss of approximately $1.5 million, or ... $2.5 million, or $0.10 per share, during the second quarter ...
... FRANCISCO, Calif., Aug. 16 Titan Pharmaceuticals, Inc. (OTC Bulletin ... the second quarter ended June 30, 2010. Total ... consisting primarily of grant and royalty revenues. Grant revenue from ... Phase 3 clinical study of Probuphine® was approximately $1.29 million, ...
Cached Medicine Technology:Nile Therapeutics Reports 2010 Second Quarter Financial Results 2Nile Therapeutics Reports 2010 Second Quarter Financial Results 3Titan Pharmaceuticals Announces Second Quarter 2010 Financial Results 2Titan Pharmaceuticals Announces Second Quarter 2010 Financial Results 3Titan Pharmaceuticals Announces Second Quarter 2010 Financial Results 4Titan Pharmaceuticals Announces Second Quarter 2010 Financial Results 5
(Date:8/21/2014)... (Boston) African American women born at a low ... higher risk for developing type 2 diabetes. The findings, ... in part the higher occurrence of type 2 diabetes ... of low birth weight. , Researchers from Boston University,s ... in the Black Women,s Health Study over the course ...
(Date:8/21/2014)... Aug. 21, 2014 (HealthDay News) -- Not only is eating ... save them hundreds of health-care dollars a year, a new ... professor of public health sciences at Wake Forest Baptist Medical ... and obese type 2 diabetes patients. Participants ... assigned to either an intensive "lifestyle change program" focused on ...
(Date:8/21/2014)... By Dennis Thompson ... (HealthDay News) -- A combination of therapy and antidepressants ... depression, a new study reports. Four out of ... two years experienced full recovery when treated with cognitive ... other hand, the combination didn,t work much better than ...
(Date:8/21/2014)... 2014 A new study published this ... in disability associated with speech problems from 2001-02 to ... 15% increase in disability associated with hearing problems. The ... numbers of children who are experiencing communication disorders, according ... , On a broader level, the new study, ...
(Date:8/21/2014)... physicians in rural communities do not routinely screen ... Penn State medical and public health researchers. Rural ... limited resources if they seek help., "Rural health ... said Jennifer S. McCall-Hosenfeld, a primary care physician ... sciences, Penn State College of Medicine. "However, in ...
Breaking Medicine News(10 mins):Health News:Low birth weight linked to higher incidence of type 2 diabetes in African American women 2Health News:Getting Healthier a Big Money-Saver for People With Diabetes 2Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 2Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 3Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 2Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 3Health News:Primary care physicians can be critical resource for abused women in rural areas 2
... Insurance,Leaders, Inc. (Amex: NAO ), today announced that ... NAO entitled to vote at the annual meeting of,stockholders ... business,combination, as presented in the NAO proxy statement dated ... to complete its proposed acquisition of the,insurance businesses of ...
... Site With Expanded Resources for Individuals With,Autism ... March 25 Danya,International, Inc. (Danya), a ... has acquired AutismOnline.org, a trusted,resource for individuals ... links parents and caregivers to support, research, ...
... (Mo.) issued the following statement today after the Social,Security ... Security and Medicare will deplete their respective trust funds ... solemn reminder that we do not have time for,further ... with the fiscal,emergency Social Security and Medicare are facing., ...
... risk of both recurrence and new malignancies surfaced , , ... more grim news concerning women and hormone replacement therapy: ... developing breast cancer while taking the therapy, breast cancer ... of a recurrence or a new malignancy. , "This ...
... Harvard-led team,s findings to be published in the American ... study scheduled,for April publication in the American Journal of ... the University of Michigan found,that women who ate the ... trimester of their pregnancies delivered children with the highest,scores ...
... It,s the time of year when more,than 1.5 million ... up the sun and drink large quantities of alcohol. Students ... as much as,those who stay home with parents or relatives, ... Journal of Studies on Alcohol and Drugs., Instead of ...
Cached Medicine News:Health News:AutismOnline.org Partners With Leading Health Communications Firm for Support 2Health News:HRT Raises Recurrence Risk Among Breast Cancer Survivors 2Health News:Study: Pregnant Women Who Eat More Fish, Including Canned Tuna, Have Smarter Children 2Health News:It's Spring Break: How Much Does Heavy Drinking Affect Your Body? 2
...
...
... Bigliani/Flatow shoulder allows for the restoration ... of shoulder replacement surgery. Backed by ... decades of experience, the Bigliani/Flatow Shoulder ... natural shoulder's mobility, balance, and stability ...
... Simplified shoulder replacement system designed ... implantation. Multiple component combinations for ... revision length porous titanium stems. ... of Bi-Polar shell diameters and ...
Medicine Products: